Related references
Note: Only part of the references are listed.Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors
Xiaoyun Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
Tasia Amelia et al.
MOLECULES (2022)
A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure-Activity Relationship
Tanuja T. Yadav et al.
FRONTIERS IN CHEMISTRY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy
Adileh Ayati et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model
Kun-Hung Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
Mohammed A. S. Abourehab et al.
MOLECULES (2021)
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
Dima A. Sabbah et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2020)
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
Adileh Ayati et al.
BIOORGANIC CHEMISTRY (2020)
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer
Shu-Yu Lin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Discovery of EGF Receptor Inhibitors That Are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design
Hwangseo Park et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
Rociletinib: has the TIGER lost a few of its stripes?
K. Dhingra
ANNALS OF ONCOLOGY (2016)
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers
Gerald Lelais et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi et al.
LANCET (2016)
AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
Xiao Xu et al.
MOLECULAR CANCER THERAPEUTICS (2016)
A new generation of EGFR inhibition
David Killock
Nature Reviews Clinical Oncology (2015)
Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
L. V. Sequist et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer
Chieh-Chien Lee et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
M. Raymond V. Finlay et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Optimization of Ligand and Lipophilic Efficiency To Identify an in Vivo Active Furano-Pyrimidine Aurora Kinase Inhibitor
Hui-Yi Shiao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Identification, SAR Studies, and X-ray Co-crystallographic Analysis of a Novel Furanopyrimidine Aurora Kinase A Inhibitor
Mohane Selvaraj Coumar et al.
CHEMMEDCHEM (2010)
Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification
Mohane Selvaraj Coumar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors
Wen-Hsing Lin et al.
ANALYTICAL BIOCHEMISTRY (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
Marissa N. Balak et al.
CLINICAL CANCER RESEARCH (2006)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Share Paper
